Lisocabtagene maraleucel (English Wikipedia)
Analysis of information sources in references of the Wikipedia article "Lisocabtagene maraleucel" in English language version.
refsWebsite
Global rank
English rank
1st place
1st place
102nd place
76th place
europa.eu
ema.europa.eu
- "Breyanzi EPAR". European Medicines Agency. 24 January 2022. Archived from the original on 24 March 2024. Retrieved 24 March 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "Breyanzi: Pending EC decision". European Medicines Agency (EMA). 28 January 2022. Archived from the original on 28 January 2022. Retrieved 28 January 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "New gene therapy treatment for patients with relapsed or refractory large B-cell lymphoma" (Press release). European Medicines Agency (EMA). 27 January 2022. Archived from the original on 28 January 2022. Retrieved 28 January 2022.
ec.europa.eu
- "Breyanzi Product information". Union Register of medicinal products. Archived from the original on 4 March 2023. Retrieved 3 March 2023.
fda.gov
- "Breyanzi (lisocabtagene maraleucel)". U.S. Food and Drug Administration (FDA). 13 November 2020. Archived from the original on 24 March 2024. Retrieved 24 March 2024.
This article incorporates text from this source, which is in the public domain. - "FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma". U.S. Food and Drug Administration (FDA) (Press release). 5 February 2021. Archived from the original on 5 March 2022. Retrieved 5 February 2021. This article incorporates text from this source, which is in the public domain.
- "FDA grants accelerated approval to Breyanzi for follicular lymphoma". U.S. Food and Drug Administration. 15 May 2024. Retrieved 18 May 2024. This article incorporates text from this source, which is in the public domain.
- "FDA Roundup: March 15, 2024". U.S. Food and Drug Administration (FDA). 15 March 2024. Archived from the original on 16 March 2024. Retrieved 24 March 2024. This article incorporates text from this source, which is in the public domain.
- "FDA approves lisocabtagene maraleucel for relapsed or refractory mantle cell lymphoma". U.S. Food and Drug Administration (FDA). 30 May 2024. Archived from the original on 25 June 2024. Retrieved 26 June 2024.
- "FDA Requires Boxed Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies". U.S. Food and Drug Administration (FDA). 18 April 2024. Archived from the original on 19 April 2024. Retrieved 19 April 2024. This article incorporates text from this source, which is in the public domain.
- "FDA approves lisocabtagene maraleucel". U.S. Food and Drug Administration. 27 June 2022. Archived from the original on 28 June 2022. Retrieved 28 June 2022. This article incorporates text from this source, which is in the public domain.
handle.net
hdl.handle.net
- World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1): 82-3. hdl:10665/330896.
hres.ca
hpr-rps.hres.ca
- "Summary Basis of Decision - Breyanzi". Health Canada. 16 August 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.
nih.gov
dailymed.nlm.nih.gov
- "Breyanzi- lisocabtagene maraleucel kit". DailyMed. Archived from the original on 24 March 2024. Retrieved 24 March 2024.
web.archive.org
- "Summary Basis of Decision - Breyanzi". Health Canada. 16 August 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.
- "Breyanzi- lisocabtagene maraleucel kit". DailyMed. Archived from the original on 24 March 2024. Retrieved 24 March 2024.
- "Breyanzi (lisocabtagene maraleucel)". U.S. Food and Drug Administration (FDA). 13 November 2020. Archived from the original on 24 March 2024. Retrieved 24 March 2024. This article incorporates text from this source, which is in the public domain.
- "Breyanzi EPAR". European Medicines Agency. 24 January 2022. Archived from the original on 24 March 2024. Retrieved 24 March 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "Breyanzi Product information". Union Register of medicinal products. Archived from the original on 4 March 2023. Retrieved 3 March 2023.
- "FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma". U.S. Food and Drug Administration (FDA) (Press release). 5 February 2021. Archived from the original on 5 March 2022. Retrieved 5 February 2021. This article incorporates text from this source, which is in the public domain.
- "FDA Roundup: March 15, 2024". U.S. Food and Drug Administration (FDA). 15 March 2024. Archived from the original on 16 March 2024. Retrieved 24 March 2024. This article incorporates text from this source, which is in the public domain.
- "FDA approves lisocabtagene maraleucel for relapsed or refractory mantle cell lymphoma". U.S. Food and Drug Administration (FDA). 30 May 2024. Archived from the original on 25 June 2024. Retrieved 26 June 2024.
- "FDA Requires Boxed Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies". U.S. Food and Drug Administration (FDA). 18 April 2024. Archived from the original on 19 April 2024. Retrieved 19 April 2024. This article incorporates text from this source, which is in the public domain.
- "FDA approves lisocabtagene maraleucel". U.S. Food and Drug Administration. 27 June 2022. Archived from the original on 28 June 2022. Retrieved 28 June 2022. This article incorporates text from this source, which is in the public domain.
- "Breyanzi: Pending EC decision". European Medicines Agency (EMA). 28 January 2022. Archived from the original on 28 January 2022. Retrieved 28 January 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "New gene therapy treatment for patients with relapsed or refractory large B-cell lymphoma" (Press release). European Medicines Agency (EMA). 27 January 2022. Archived from the original on 28 January 2022. Retrieved 28 January 2022.